Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Key Points On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses ...

Dewpoint Therapeutics, a startup working in the once-buzzy field of biomolecular condensates, has laid off most of its staff.

This may sound familiar if you’re subscribed to my AI Prognosis newsletter, but it’s worth repeating: I finally found time to ...

Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

One of the most notable accomplishments of the first Trump Administration was its willingness to take on the status quo of ...